<span item_type="fundamental" item_id="f08b9993bbbc383f61458492f9300306" counter_id="ST/US/TOVX" env="prod"></span><span item_type="announcement" item_id="645119865082617473" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 300 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.05, meeting the estimate of USD -0.05.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -2.209 M.</p><p></p><h4>License Revenue</h4><p>License Revenue was $300,000 for the three months ended March 31, 2026, compared to $0 for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p><h4>Operating Costs and Expenses</h4><ul><li>General and administrative expenses increased to $2.1 million for the three months ended March 31, 2026, from $1.4 million for the three months ended March 31, 2025, representing a 43% increase, primarily due to higher legal fees, investor relations costs, registration fees, and salary costs <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. Stock-based compensation expense for general and administrative expenses was $111,000 for Q1 2026, up from $54,000 for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</li><li>Research and development expenses decreased to $355,000 for the three months ended March 31, 2026, from approximately $3.0 million for the three months ended March 31, 2025, an 88% decrease, mainly due to lower clinical trial expenses following the completion of the VIRAGE Phase 2b trial of VCN-01 in PDAC, the recognition of the Spanish R&amp;D rebate, and lower indirect compensation costs, partially offset by higher patent expenses for SYN-020 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. Stock-based compensation expense for research and development was $24,000 for Q1 2026, down from $46,000 for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</li><li>Total Operating Costs and Expenses were $2.427 million for Q1 2026, compared to $4.417 million for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</li></ul><h4>Loss from Operations</h4><p>Loss from Operations was - $2.127 million for the three months ended March 31, 2026, compared to - $4.417 million for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p><h4>Other Income</h4><p>Total Other Income was $83,000 for the three months ended March 31, 2026, compared to $93,000 for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. This included $82,000 in interest income and a $1,000 exchange gain for Q1 2026, while Q1 2025 included $96,000 in interest income and a - $3,000 exchange loss <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p><h4>Net Loss Attributable to Common Stockholders</h4><p>Net Loss Attributable to Common Stockholders was - $2.044 million for the three months ended March 31, 2026, compared to - $4.324 million for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p><h4>Cash and Cash Equivalents</h4><p>Cash and cash equivalents totaled $14.4 million as of March 31, 2026, an increase of $1.4 million from December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. Theriva Biologics, Inc. reported a cash runway into Q1 2027 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p><h4>Operational Outlook</h4><p>Theriva Biologics, Inc. plans a small dosing feasibility study in Spain for VCN-01 in PDAC in the second half of 2026 and aims for potential first patient enrollment in a Phase <sup>2</sup>⁄<sub>3</sub> clinical trial for VCN-01 in retinoblastoma in December 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. Rolling Biologic Licensing Application submissions are targeted for 2029, with approval sought before September 30, 2029 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>. Research and development expenses are anticipated to decrease in the near future until additional clinical trials commence <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm"></span>.</p>

Theriva Biologics | 8-K: FY2026 Q1 Revenue: USD 300 K